The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Helmy M. Siragy

PO Box 801409

University of Virginia Health System

Charlottesville

VA 22908-1409

[email]@virginia.edu

Name/email consistency: medium

 
 
 
 
 
 
 

Affiliations

  • PO Box 801409, University of Virginia Health System, Charlottesville, VA 22908-1409. 2012
  • Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia Health System, Charlottesville, USA. 1997 - 2011

References

  1. Sodium Depletion Enhances Renal Expression of (Pro)Renin Receptor via Cyclic GMP-Protein Kinase G Signaling Pathway. Huang, J., Siragy, H.M. Hypertension (2012) [Pubmed]
  2. Rationale for combining a direct renin inhibitor with other renin- angiotensin system blockers. Focus on aliskiren and combinations. Siragy, H.M. Cardiovasc. Drugs. Ther (2011) [Pubmed]
  3. Angiotensin AT₂ receptor stimulation inhibits early renal inflammation in renovascular hypertension. Matavelli, L.C., Huang, J., Siragy, H.M. Hypertension (2011) [Pubmed]
  4. Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Siragy, H.M., Carey, R.M. Am. J. Nephrol. (2010) [Pubmed]
  5. The angiotensin II type 2 receptor and the kidney. Siragy, H.M. J. Renin. Angiotensin. Aldosterone. Syst (2010) [Pubmed]
  6. Comparing angiotensin II receptor blockers on benefits beyond blood pressure. Siragy, H.M. Adv. Ther (2010) [Pubmed]
  7. Improving vascular function in hypertension: potential benefits of combination therapy with amlodipine and renin-angiotensin-aldosterone system blockers. Siragy, H.M. J. Hypertens. (2010) [Pubmed]
  8. The potential role of the angiotensin subtype 2 receptor in cardiovascular protection. Siragy, H.M. Curr. Hypertens. Rep. (2009) [Pubmed]
  9. ACCOMPLISH the goal: hypertension and beyond. Siragy, H.M. Curr. Hypertens. Rep. (2009) [Pubmed]
  10. Evidence for benefits of angiotensin receptor blockade beyond blood pressure control. Siragy, H.M. Curr. Hypertens. Rep. (2008) [Pubmed]
  11. The development of the direct renin inhibitor aliskiren: treating hypertension and beyond. Siragy, H., Huang, J., Lieb, D.C. Expert. Opin. Emerg. Drugs (2008) [Pubmed]
  12. Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats. Siragy, H.M., Xue, C. Exp. Physiol. (2008) [Pubmed]
  13. Renal (pro)renin receptor upregulation in diabetic rats through enhanced angiotensin AT1 receptor and NADPH oxidase activity. Siragy, H.M., Huang, J. Exp. Physiol. (2008) [Pubmed]
  14. NO and cGMP mediate angiotensin AT2 receptor-induced renal renin inhibition in young rats. Siragy, H.M., Inagami, T., Carey, R.M. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2007) [Pubmed]
  15. Renin inhibition: a new modality for hypertension management. Siragy, H.M. Curr. Hypertens. Rep. (2007) [Pubmed]
  16. TROPHY for preventing hypertension. Siragy, H.M. Curr. Hypertens. Rep. (2007) [Pubmed]
  17. Angiotensin AT1 and AT2 receptors--the battle for health and disease. Siragy, H.M. Nephrol. Dial. Transplant. (2007) [Pubmed]
  18. Angiotensin II compartmentalization within the kidney: effects of salt diet and blood pressure alterations. Siragy, H.M. Curr. Opin. Nephrol. Hypertens. (2006) [Pubmed]
  19. Beneficial effects of combined benazepril-amlodipine on cardiac nitric oxide, cGMP, and TNF-alpha production after cardiac ischemia. Siragy, H.M., Xue, C., Webb, R.L. J. Cardiovasc. Pharmacol. (2006) [Pubmed]
  20. Angiotensin subtype-2 receptors inhibit renin biosynthesis and angiotensin II formation. Siragy, H.M., Xue, C., Abadir, P., Carey, R.M. Hypertension (2005) [Pubmed]
  21. Clinical trials report. Beta-blockade in diabetes: alleviating the concerns. Siragy, H.M. Curr. Hypertens. Rep. (2005) [Pubmed]
  22. AT1 and AT2 receptor in the kidney: role in health and disease. Siragy, H.M. Semin. Nephrol. (2004) [Pubmed]
  23. The angiotensin II type 1 receptor mediates renal interstitial content of tumor necrosis factor-alpha in diabetic rats. Siragy, H.M., Awad, A., Abadir, P., Webb, R. Endocrinology (2003) [Pubmed]
  24. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitors or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Siragy, H.M. Curr. Hypertens. Rep. (2003) [Pubmed]
  25. Differences in AT2 -receptor stimulation between AT1 -receptor blockers valsartan and losartan quantified by renal interstitial fluid cGMP. Siragy, H.M., El-Kersh, M.A., De Gasparo, M., Webb, R.L., Carey, R.M. J. Hypertens. (2002) [Pubmed]
  26. Angiotensin receptor blockers: how important is selectivity?. Siragy, H.M. Am. J. Hypertens. (2002) [Pubmed]
  27. Angiotensin type 2 receptors: potential importance in the regulation of blood pressure. Siragy, H.M., Carey, R.M. Curr. Opin. Nephrol. Hypertens. (2001) [Pubmed]
  28. Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP. Siragy, H.M., de Gasparo, M., El-Kersh, M., Carey, R.M. Hypertension (2001) [Pubmed]
  29. Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. Siragy, H.M., de Gasparo, M., Carey, R.M. Hypertension (2000) [Pubmed]
  30. Prospective trials of angiotensin receptor blockers: beyond blood pressure control. Siragy, H.M., Carey, R.M. Curr. Hypertens. Rep. (2000) [Pubmed]
  31. AT(1) and AT(2) receptors in the kidney: role in disease and treatment. Siragy, H.M. Am. J. Kidney Dis. (2000) [Pubmed]
  32. Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model. Siragy, H.M., Carey, R.M. Hypertension (1999) [Pubmed]
  33. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. Siragy, H.M., Carey, R.M. J. Clin. Invest. (1997) [Pubmed]
 
WikiGenes - Universities